{"schema_version":"secwatch.filing_event.v1","accession":"0001636282-26-000083","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2026-06-15T12:01:32+00:00","discovered_at":"2026-06-15T12:05:16.426500+00:00","generated_at":"2026-06-15T12:06:33.699398+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Spyre reports positive Phase 2 topline data for SPY002 in ulcerative colitis; met primary endpoint","bullets":["SPY002 achieved primary endpoint: 10.7-point RHI reduction (p<0.0001) at 12 weeks.","Clinical remission rate 33%, endoscopic improvement rate 42%, modified Mayo Score change -3.7.","Well tolerated; safety profile consistent with TL1A class; no drug-related SAEs.","Two SAEs (UC exacerbation, heart failure) deemed not drug-related; no deaths.","Company on track to report SPY003 Part A data in Q3 2026 and enrolling Part B."],"urls":{"canonical":"https://secwatch.observer/filing/0001636282-26-000083","json":"https://secwatch.observer/filing/0001636282-26-000083.json","markdown":"https://secwatch.observer/filing/0001636282-26-000083.md","text":"https://secwatch.observer/filing/0001636282-26-000083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000083/0001636282-26-000083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000083/syre-20260615.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T12:06:33.699398+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}